title: Progress report on new antiepileptic drugs: a summary of the Third Eilat Conference.
abstract: The Third Eilat Conference on New Antiepileptic Drugs was held at the Royal Beach Hotel from May 27 to May 30, 1996. Epileptologists and scientists from 20 countries attended the conference, which was held to discuss critical issues in drug development, new antiepileptic drugs (AEDs) in development, progress reports and recent findings of newly marketed AEDs, the use of AEDs in special populations and their utilization in non-epileptic disorders. Over the last seven years, six new AEDs have been introduced worldwide and new information on their safety and efficacy has become available. These include felbamate, gabapentin, lamotrigine, oxcarbazepine, topiramate and vigabatrin. Drugs in development include those at an advanced stage, such as remacemide and tiagabine, as well as those just entering clinical trials, such as rufinamide (CGP 331010) and levetiracetam (ucb LO59). The following is a summary of the presentations for drugs in development and recent findings on newly marketed drugs.
authors.affiliation: School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Israel.
authors.forename: M
authors.initials: M
authors.lastname: Bialer
authors.forename: S I
authors.initials: SI
authors.lastname: Johannessen
authors.forename: H J
authors.initials: HJ
authors.lastname: Kupferberg
authors.forename: R H
authors.initials: RH
authors.lastname: Levy
authors.forename: P
authors.initials: P
authors.lastname: Loiseau
authors.forename: E
authors.initials: E
authors.lastname: Perucca
mesh_terms: D000081:Acetamides / Q000627:therapeutic use; D000818:Animals; D000927:Anticonvulsants / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001384:Azetidines / Q000627:therapeutic use; D002219:Carbamates / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D015507:Drugs, Investigational / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004827:Epilepsy / Q000188:drug therapy*; D006801:Humans; D007557:Israel; D000077287:Levetiracetam; D009557:Nipecotic Acids / Q000627:therapeutic use; D010655:Phenylenediamines / Q000627:therapeutic use; D010889:Piracetam / Q000031:analogs & derivatives / Q000627:therapeutic use; D011358:Product Surveillance, Postmarketing; D016032:Randomized Controlled Trials as Topic; D013844:Thiazoles / Q000627:therapeutic use; D000078308:Tiagabine; D014230:Triazoles / Q000627:therapeutic use
chemical_list: D000081:Acetamides; D000927:Anticonvulsants; D001384:Azetidines; D002219:Carbamates; D015507:Drugs, Investigational; D009557:Nipecotic Acids; D010655:Phenylenediamines; D013844:Thiazoles; D014230:Triazoles; C101866:ezogabine; D000077287:Levetiracetam; C064672:AHR 11748; C067553:remacemide; C054894:Ralitoline; C079703:rufinamide; D000078308:Tiagabine; D010889:Piracetam